News
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Approval of extension of exemptions from SIX disclosure and publicity obligations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an
Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis
Charles River Launches HemaCare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of a new digital donor experience to enhance access to its donor centers in four distinct US geographic markets
Premier, Inc. Issues 2022 Sustainability Report
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today released its 2022 Sustainability Report detailing its companywide initiatives focused on
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
Charles River Laboratories International, Inc. (NYSE: CRL) and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases
Chemed To Report Third-Quarter 2022 Earnings October 31, Related Conference Call To Be Held On November 1
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2022, on Monday, October 31, 2022, following the close of trading on
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Premier, Inc.'s Subsidiary Contigo Health, LLC, Completes Asset Transaction for National Provider Contracts and Licenses to Cost Containment Technology
Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today closed its transaction to acquire key assets from
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Approval of delisting of Vifor Pharma AG's registered shares
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's
GI Genius™ named to FORTUNE 2022 “Change the World” list
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2022 financial results on Wednesday, November 2nd, before the market opens. A conference call has been
Acadia Healthcare Announces Date for Third Quarter 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2022 results on Monday, October 31, 2022, after the close of the market. Acadia will conduct a
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sonova Investor & Analyst Day 2022: Leading innovation and further expanding our reach
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation™ Vector Platform (nAAVigation). Leveraging decades of Adeno-Associated Virus (AAV) vector
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Kapruvia® (Difelikefalin) jetzt in Deutschland für Hämodialysepatient:innen mit CKD-assoziiertem Pruritus erhältlich
CSL Vifor gab heute die Markteinführung von Kapruvia® zur Behandlung von mäßigem bis schwerem Juckreiz im Zusammenhang mit CKD bei Erwachsenen bekannt, die sich einer Hämodialyse unterziehen.1 Kapr
